Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoRaLa II trial
2023-507816-11-00Phase 3Authorised
- Sponsor
- Justus Liebig University Giessen
- Start
- Oct 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised trial of ranibizumab in macular edema (2 arms), sponsored by Justus Liebig University Giessen. Primary endpoint: Time to treatment success. Planned start Oct 2023; status: authorised.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on 2023-507816-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507816-11-00.